AEON Biopharma, Inc. financial data

Symbol
AEON on NYSE
Location
Irvine, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 79% % 161%
Debt-to-equity -149% % -43%
Return On Equity -59% %
Return On Assets 0% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,838,447 shares -70%
Common Stock, Shares, Outstanding 11,643,786 shares -71%
Entity Public Float $17,000,000 USD 20%
Common Stock, Value, Issued $9,000 USD 125%
Weighted Average Number of Shares Outstanding, Basic 11,634,946 shares 2019%
Weighted Average Number of Shares Outstanding, Diluted 11,634,946 shares 2019%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,524,000 USD -39%
Operating Income (Loss) $9,615,000 USD 38%
Nonoperating Income (Expense) $9,612,000 USD 5.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $3,000 USD 26%
Net Income (Loss) Attributable to Parent $3,000 USD 26%
Earnings Per Share, Basic 14 USD/shares 97%
Earnings Per Share, Diluted 9 USD/shares 97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,927,000 USD 1004%
Assets, Current $7,412,000 USD 213%
Property, Plant and Equipment, Net $181,000 USD -30%
Operating Lease, Right-of-Use Asset $1,112,000 USD -17%
Other Assets, Noncurrent $29,000 USD 0%
Assets $8,734,000 USD 118%
Accounts Payable, Current $2,525,000 USD -45%
Employee-related Liabilities, Current $1,547,000 USD -1%
Liabilities, Current $8,228,000 USD -23%
Operating Lease, Liability, Noncurrent $957,000 USD -21%
Liabilities $28,606,000 USD -21%
Retained Earnings (Accumulated Deficit) $433,682,000 USD -0%
Stockholders' Equity Attributable to Parent $19,872,000 USD 38%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $28,569,000 USD 81%
Liabilities and Equity $8,734,000 USD 118%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,909,000 USD 8%
Net Cash Provided by (Used in) Financing Activities $18,346,000 USD 267%
Common Stock, Shares Authorized 1,040,000,000 shares 108%
Common Stock, Shares, Issued 11,643,786 shares -71%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,433,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5,927,000 USD 1004%
Deferred Tax Assets, Valuation Allowance $59,560,000 USD 10%
Deferred Tax Assets, Gross $60,985,000 USD 13%
Operating Lease, Liability $1,204,000 USD -9.6%
Payments to Acquire Property, Plant, and Equipment $4,000 USD
Lessee, Operating Lease, Liability, to be Paid $1,323,000 USD -12%
Property, Plant and Equipment, Gross $506,000 USD 0.8%
Operating Lease, Liability, Current $247,000 USD 93%
Lessee, Operating Lease, Liability, to be Paid, Year Two $307,000 USD 3.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $297,000 USD 70%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $119,000 USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Three $318,000 USD 3.6%
Deferred Tax Assets, Operating Loss Carryforwards $35,966,000 USD 26%
Unrecognized Tax Benefits $16,115,000 USD 9.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four $329,000 USD 3.5%
Operating Lease, Payments $72,000 USD -10%
Additional Paid in Capital $413,801,000 USD 3%
Depreciation, Depletion and Amortization $19,000 USD -24%
Deferred Tax Assets, Net of Valuation Allowance $1,425,000 USD 831%
Share-based Payment Arrangement, Expense $1,000,000 USD -38%